Ireland - acetylsalicylic acid

Fast access to acetylsalicylic acid safeguards cardiovascular care

Ireland

Critical availability of anticoagulant therapy under pressure

Timely access to medication that helps prevent blood clotting is essential for patients at increased risk of cardiovascular disease. When availability comes under pressure, it can have direct consequences for continuity of care and patient safety.

In Ireland, a situation arose in which a low dose of the active ingredient acetylsalicylic acid became difficult to obtain. This case demonstrates how speed and international reach can make a difference in critical situations.

Risk of interruption to preventive treatment

On February 18, 2026, an urgent request was submitted for a low dose of the active ingredient acetylsalicylic acid, used to prevent blood clots and reduce the risk of heart attacks and strokes.

Limited availability in Ireland put pressure on the continuity of this preventive therapy. Without rapid intervention, treatment interruption threatened, with potential consequences for patient safety and healthcare capacity.

Rapid sourcing through Orphamed’s international network

Orphamed was engaged to find a suitable alternative with the same active ingredient and acted immediately. Thanks to its extensive international supplier network, Orphamed quickly secured access to a suitable variant despite limited market availability.

Through efficient coordination and strategic procurement, Orphamed delivered a fast and cost-effective solution tailored to the client’s needs.

Continuity of care ensured through rapid delivery

Thanks to Orphamed’s rapid sourcing and delivery, access to this essential therapy remained secured. The client received the required medication in time, allowing patients to continue their treatment without interruption.

This case highlights how crucial rapid access to medication is within cardiovascular care and demonstrates the value of a reliable partner during times of shortage.